Skip to main content
. 2017 Aug 31;102(11):1842–1849. doi: 10.3324/haematol.2017.174953

Figure 3.

Figure 3.

Achievement of major molecular response on frontline imatinib and second-generation tyrosine kinase inhibitors. (A) Cumulative incidence of MMR on initial treatment. (B) Cumulative incidence of overall MMR achievement (including patients who switched TKI). MMR: major molecular response; 2GTKI: second-generation tyrosine kinase inhibitors.